Current Report Filing (8-k)
August 08 2017 - 5:22PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): August 7, 2017
Inotek Pharmaceuticals Corporation
(Exact name of registrant as specified in its charter)
|
|
|
|
|
DELAWARE
|
|
001-36829
|
|
04-3475813
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
91 Hartwell Avenue
Lexington, MA
|
|
02421
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code (781)
676-2100
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the
Form 8-K
filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to
Rule 14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to
Rule 14d-2(b) under
the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to
Rule 13e-4(c) under
the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 or Rule
12b-2
of the Securities Exchange Act of 1934.
Emerging
growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.
|
On August 7, 2017, the Company entered into an amendment to the Offer Letter, dated as of May 2, 2007 and amended on
December 23, 2008 and October 9, 2009 (the Offer Letter), with Rudolf A. Baumgartner, M.D., the Executive Vice President, Chief Medical Officer of Inotek Pharmaceuticals Corporation (the Company) (the
Amendment). Under the Amendment, in the event of a Change of Control (as defined in the Offer Letter), Dr. Baumgartners outstanding unvested equity awards will be fully vested upon his execution of a comprehensive release of
claims in the Companys favor.
The description of the Amendment set forth herein does not purport to be complete and is qualified in
its entirety by reference to the full text thereof, which is attached hereto as Exhibit 10.1.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
|
|
|
Exhibit
No.
|
|
Description
|
|
|
10.1
|
|
Amendment to Offer Letter, effective as of August 7, 2017, by and between the Company and Rudolf A. Baumgartner, M.D.
|
* * *
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
Date: August 8, 2017
|
|
|
|
INOTEK PHARMACEUTICALS CORPORATION
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Dale Ritter
|
|
|
|
|
|
|
Dale Ritter
|
|
|
|
|
|
|
Vice President Finance
|
EXHIBIT INDEX
|
|
|
Exhibit
No.
|
|
Description
|
|
|
10.1
|
|
Amendment to Offer Letter, effective as of August 7, 2017, by and between the Company and Rudolf A. Baumgartner, M.D.
|
INOTEK PHARMACEUTICALS CORP (NASDAQ:ITEK)
Historical Stock Chart
From Mar 2024 to Apr 2024
INOTEK PHARMACEUTICALS CORP (NASDAQ:ITEK)
Historical Stock Chart
From Apr 2023 to Apr 2024